Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
COVID-19
Task force offers tools allowing patients on ventilators to communicate
For a patient suffering from a life-threatening illness like COVID-19, communication means everything. If that person is on a ventilator and no visitors are allowed in the room, doctors and nurses must rely on tools …